Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in
allogeneic cellular medicines for inflammatory diseases, today
reported operational highlights and financial results for the first
quarter ended September 30, 2021.
“We are pleased to have entered into a strategic financing
partnership with leading global investment management firm Oaktree
Capital as we focus on bringing our first product to the US market
and in line with our commercial growth strategy over the next five
years,” said Silviu Itescu, Chief Executive of Mesoblast”
Financial & Operational Highlights
- Successfully entered into a refinancing and expansion of our
senior debt facility with Oaktree Capital Management. The new US$90
million, 5-year secured facility has a 3-year interest only period
after which time 40% of the principal amortizes over two years and
a final payment due no later than November 2026.
- Cash on hand at the end of the quarter was US$116.0
million
- Revenues from TEMCELL® HS Inj.1 royalties in Japan were US$2.4
million, an increase of 22% on the previous quarter, and of 90% on
the comparative quarter last year
- Net cash operating usage was US$19.6 million for the quarter, a
reduction of US$8.6 million on the comparative quarter
- Loss after tax improved US$1.9 million on the comparative
quarter
- Results published in the latest issue of the peer-reviewed
journal Bone Marrow Transplantation2 showed that children with
steroid-refractory acute graft versus host disease (SR-aGVHD) and
biomarkers predictive for highest mortality had 64% survival when
treated with remestemcel-L compared with only 10% survival when
treated with other available therapies, including ruxolitinib or
other biologics
- These data provide further support for the proposed
anti-inflammatory mechanism of action of remestemcel-L and its
immunomodulatory activity in patients with SR-aGVHD, resulting in
improved survival outcomes
- At the upcoming scheduled meeting with United States Food &
Drug Administration’s (FDA) Office of Tissue and Advanced Therapies
(OTAT), Mesoblast will address the appropriateness of potency
assays related to remestemcel-L’s proposed anti-inflammatory
mechanism of action as well as the outstanding chemistry,
manufacturing and controls (CMC) items which could support a
resubmission of the current Biologics License Application (BLA) for
remestemcel-L in the treatment of SR-aGVHD in children
- Mesoblast met with the FDA in regard to potential emergency use
authorization (EUA) for remestemcel-L in the treatment of
ventilator-dependent patients with moderate or severe acute
respiratory distress syndrome (ARDS) due to COVID-19. The FDA
advised that an additional clinical study which showed
statistically positive outcomes in conjunction with the recently
completed 222 patient trial may be sufficient to provide a dataset
in support of an EUA
- Results from the randomized, controlled Phase 3 trial of
rexlemestrocel-L in 565 patients with New York Heart Association
(NYHA) class II and class III chronic heart failure (CHF) with low
ejection fraction (HFrEF) were presented as a late breaking
presentation at the American Heart Association (AHA) annual
Scientific Sessions during a featured program titled ‘Building on
the Foundations of Treatment: Advances in Heart Failure
Therapy’
- The trial’s co-principal investigator Dr Emerson Perin, Medical
Director of Texas Heart Institute, and Clinical Professor, Baylor
College of Medicine, presented new results from the landmark study
showing a significant relationship between presence of systemic
inflammation as quantified by high-sensitivity C-reactive protein
(hs-CRP) and treatment benefit with rexlemestrocel-L on risk of
cardiovascular mortality, heart attacks or strokes
- Mesoblast is in ongoing discussions with the FDA on the
potential pathways to US regulatory approval for its
rexlemestrocel-L product candidate in heart failure patients at
high risk of cardiovascular mortality, heart attacks or
strokes
DETAILED CLINICAL ACTIVITIES DURING FOR THE
PERIOD
Remestemcel-L
Steroid-refractory acute graft versus host disease
(SR-aGVHD) in children:
Results published in the peer-reviewed journal Bone Marrow
Transplantation2 showed that children with SR-aGVHD and biomarkers
predictive for highest mortality had 64% survival when treated with
remestemcel-L compared with only 10% survival when treated with
other available therapies.
The study compared outcomes in 25 children from Mesoblast’s
Phase 3 trial of remestemcel-L in SR-aGVHD with 27 closely matched
children from the Mount Sinai Acute GVHD International Consortium
(MAGIC)3 who participated in a prospective natural history study
and were matched for the Phase 3 trial entry criteria. The
objective of the study was to evaluate whether outcomes differed
according to treatment with remestemcel-L vs other therapies in
children at highest risk of death, namely those with baseline MAGIC
Algorithm Probability (MAP) biomarker levels ≥0.291, a level
predictive of very high mortality and poor responses to therapy in
SR-aGVHD. MAP combines the serum concentrations of two biomarkers,
Reg3α and ST2, into a single value that predicts long-term outcomes
and significant GI tract damage.
MAP levels ≥0.291 were present in 48% of remestemcel-L treated
children (12/25) and 37% of the MAGIC cohort (10/27). Treatment
with remestemcel-L resulted in 67% Day 28 Overall Response and 64%
Day 180 overall survival compared with 10% Day 28 Overall Response
and 10% Day 180 survival in the MAGIC cohort (both p=0.01) when
treated with various biologics, including ruxolitinib. These
results extend previous observations showing that children who
achieved clinically meaningful responses and survival after
treatment with remestemcel-L had significant reductions in the ST2
biomarker of inflammation, consistent with healing of the GI
tract.4
These data provide further support for the proposed
anti-inflammatory mechanism of action of remestemcel-L and its
immunomodulatory activity in patients with SR-aGVHD, resulting in
improved survival outcomes. At its upcoming scheduled meeting with
FDA’s OTAT, Mesoblast will address the appropriateness of potency
assays related to remestemcel-L’s proposed anti-inflammatory
mechanism of action as well as the outstanding CMC items which
could support a resubmission of the current BLA for remestemcel-L
in the treatment of SR-aGVHD in children with a six month
review.
Acute Respiratory Distress Syndrome (ARDS) due to
COVID-19
Early this quarter, Mesoblast met with the FDA in regard to
potential EUA for remestemcel-L in the treatment of
ventilator-dependent patients with moderate or severe ARDS due to
COVID-19. The FDA advised Mesoblast that an additional clinical
study in COVID ARDS would be required which, if statistically
positive, could provide a dataset in conjunction with the recently
completed 222 patient clinical study that might be sufficient to
support an EUA
FDA provided guidance that the existing COVID ARDS
Investigational New Drug (IND) file and future submissions for
remestemcel-L in this indication may continue to cross-reference
manufacturing information in BLA 125706 for pediatric SR-aGVHD.
FDA indicated that potency assays must be established and agreed
prior to commencement of the proposed Phase 3 clinical trial. FDA
indicated that the potency assays currently in development appeared
to be reasonable based on in vitro results provided in the briefing
document, the in vitro activity of the product appears to be
relatively well established, though the relationship between in
vitro activity and the product’s actual mechanism of action remains
theoretical.
Mesoblast has entered into a license and collaboration agreement
with Novartis for the development, manufacture, and
commercialization of remestemcel-L, with an initial focus on the
treatment of acute respiratory distress syndrome (ARDS) including
that associated with COVID-19. The agreement remains subject to
certain closing conditions, including time to analyze the results
from the COVID-19 ARDS trial.
Mesoblast plans to move forward with an additional Phase 3 trial
in COVID-19 ARDS with the next step being to agree with the FDA the
final protocol and potency assay.
Rexlemestrocel-L
Chronic Heart Failure
Data from the randomized, controlled Phase 3 trial of
rexlemestrocel-L in 565 patients with NYHA class II and class III
HFrEF were presented as a late breaking presentation at the AHA
annual Scientific Sessions during a featured program titled
‘Building on the Foundations of Treatment: Advances in Heart
Failure Therapy.’
The trial’s co-principal investigator Dr Emerson Perin, Medical
Director of Texas Heart Institute, and Clinical Professor, Baylor
College of Medicine, presented new results from the landmark study
showing a significant relationship between presence of systemic
inflammation as quantified by high-sensitivity C-reactive protein
(hs-CRP) and treatment benefit with rexlemestrocel-L on risk of
cardiovascular mortality, heart attacks or strokes
The presentation highlighted that a single dose of
rexlemestrocel-L on top of standard care versus standard of care
alone:
- Reduced the incidence of heart attacks or strokes across all
537 NYHA class II or class III treated patients
- Reduced the incidence of heart attacks or strokes by an even
greater amount in 301 patients with high levels inflammation
- Reduced the incidence of cardiovascular death in NYHA class II
patients with the greatest effect seen in patients with high levels
of inflammation
- Did not further reduce the frequency of hospitalization for
worsening HF symptoms as previously reported
Whereas most traditional treatments address the congestion or
fluid overload associated with heart failure, rexlemestrocel-L
addresses the inflammation that is at the centre of advanced
chronic heart failure – widely regarded as the leading cause of
death in the developed world.
The ability of rexlemestrocel-L to significantly impact cardiac
death, heart attacks and strokes on top of maximal HFrEF therapy
reflects the unique mechanisms-of-action of this allogeneic
cellular therapy on reduction of inflammation and improved
microvasculature. The unchecked intra-cardiac inflammation in HFrEF
patients causes progressive loss of heart muscle, replacement with
scar tissue, and death. Persistent inflammation in the blood
circulation also results in accelerated atherosclerosis with plaque
progression and instability resulting in plaque rupture and
potential blockage of major arteries, resulting in high rates of
heart attacks and strokes in chronic HFrEF patients.
Rexlemestrocel-L is believed to reduce inflammatory cytokine
production by immune cells, generating improved local networks of
blood vessels within the damaged heart and reducing risk of plaque
rupture in major arteries. The observed relationship between
systemic inflammation and degree of benefit from treatment with
rexlemestrocel-L supports the importance of the anti-inflammatory
mechanism-of-action of rexlemestrocel-L in addressing the high-risk
of mortality and morbidity in HFrEF patients.
DETAILED FINANCIAL HIGHLIGHTS FOR THE THREE MONTHS ENDED
SEPTEMBER 30, 2021 (FIRST QUARTER FY2022)
- Cash on hand at the end of the quarter was
US$116.0 million
- Net operating cash usage was US$19.6 million
for the quarter, a reduction of US$8.6 million on the comparative
quarter.
- Total Revenue was US$3.6 million for the first
quarter FY2022, an increase of US$2.3 million on the comparative
quarter due to growth in royalties and US$1.2 million of milestone
revenue given Takeda received approval to manufacture and market
Alofisel® (darvadstrocel) in Japan for the treatment of complex
perianal fistulas in patients with non-active or mildly active
luminal Crohn’s Disease.
Within revenue, royalties from TEMCELL® HS Inj.1 in Japan were
US$2.4 million, an increase of 22% on the previous quarter, and of
90% on the comparative quarter last year.
- Research & Development expenses reduced by
US$10.0 million (52%), down to US$9.3 million for the first quarter
FY2022 from US$19.3 million for the first quarter FY2021 as
clinical trial activities for our COVID-19 ARDS, CLBP and CHF
product candidates reduced given clinical trial recruitment and
data analysis is now complete.
- Manufacturing expense reduced by US$4.4
million (37%) down to US$7.5 million for the first quarter FY2022
from US$11.9 million for the first quarter FY2021 due to a
reduction in process development activities. During the quarter we
continued to build our pre-launch inventory levels of remestemcel-L
to support the long-term commercial supply for SR-aGVHD and COVID
ARDS.
We expect to recognize the US$26.0 million balance of
remestemcel-L pre-launch inventory, and the balance of any further
production completed at that time, on our balance sheet if we
receive FDA approval.
- Management and Administration reduced by
US$1.8 million (23%), down to US$5.9 million for the first quarter
FY2022 from US$7.7 million for the first quarter FY2021 as employee
compensation costs were reduced.
- Remeasurement of Contingent Consideration
reduced to a gain of US$0.3 million for the first quarter FY2022
whereas a gain of US$15.1 million was recognized in the first
quarter FY2021 reflecting a reduction in future third party
payments.
- Finance Costs predominantly for borrowing
arrangements with Hercules and NovaQuest were US$3.6 million for
the first quarter FY2022, compared to US$2.9 million for the first
quarter FY2021.
Loss after tax improved US$1.9 million, down to US$22.6 million
for the first quarter FY2022 compared to US$24.5 million for the
first quarter FY2021.The net loss attributable to ordinary
shareholders was 3.49 US cents per share for the first quarter
FY2022, compared with 4.21 US cents per share for the first quarter
FY2021.
Conference Call
There will be a webcast today, beginning at 9.00am AEDT
(Wednesday, November 24); 5.00pm EST (Tuesday, November 23). It can
be accessed via: https://webcast.openbriefing.com/8205/
The archived webcast will be available on the Investor page of
the Company’s website: www.mesoblast.com
About Mesoblast
Mesoblast is a world leader in developing allogeneic
(off-the-shelf) cellular medicines for the treatment of severe and
life-threatening inflammatory conditions. The Company has leveraged
its proprietary mesenchymal lineage cell therapy technology
platform to establish a broad portfolio of late-stage product
candidates which respond to severe inflammation by releasing
anti-inflammatory factors that counter and modulate multiple
effector arms of the immune system, resulting in significant
reduction of the damaging inflammatory process.
Mesoblast has a strong and extensive global intellectual
property portfolio with protection extending through to at least
2041 in all major markets. The Company’s proprietary manufacturing
processes yield industrial-scale, cryopreserved, off-the-shelf,
cellular medicines. These cell therapies, with defined
pharmaceutical release criteria, are planned to be readily
available to patients worldwide.
Mesoblast is developing product candidates for distinct
indications based on its remestemcel-L and rexlemestrocel-L stromal
cell technology platforms. Remestemcel-L is being developed for
inflammatory diseases in children and adults including steroid
refractory acute graft versus host disease and moderate to severe
acute respiratory distress syndrome. Rexlemestrocel-L is in
development for advanced chronic heart failure and chronic low back
pain. Two products have been commercialized in Japan and Europe by
Mesoblast’s licensees, and the Company has established commercial
partnerships in Europe and China for certain Phase 3 assets.
Mesoblast has locations in Australia, the United States and
Singapore and is listed on the Australian Securities Exchange (MSB)
and on the Nasdaq (MESO). For more information, please see
www.mesoblast.com, LinkedIn: Mesoblast Limited and Twitter:
@Mesoblast
References / Footnotes
- TEMCELL® HS Inj. is a registered trademark of JCR
Pharmaceuticals Co. Ltd.
- Kasikis S., et al. Mesenchymal stromal cell therapy induces
high responses and survival in children with steroid refractory
GVHD and poor risk. Bone Marrow Transplantation 2021;
https://doi.org/10.1038/s41409-021-01442-3
- Mount Sinai Acute GVHD International Consortium (MAGIC) - a
group of ten BMT centers throughout the US and Europe whose purpose
is to conduct ground-breaking clinical trials in GVHD, including
developing informative biorepositories that assist in developing
treatments that can guide GVHD therapy
- Presented at the annual meeting of the American Society of
Hematology (ASH) 2020
Forward-Looking Statements
This announcement includes forward-looking statements that
relate to future events or our future financial performance and
involve known and unknown risks, uncertainties and other factors
that may cause our actual results, levels of activity, performance
or achievements to differ materially from any future results,
levels of activity, performance or achievements expressed or
implied by these forward-looking statements. We make such
forward-looking statements pursuant to the safe harbor provisions
of the Private Securities Litigation Reform Act of 1995 and other
federal securities laws. Forward-looking statements should not be
read as a guarantee of future performance or results, and actual
results may differ from the results anticipated in these
forward-looking statements, and the differences may be material and
adverse. Forward-looking statements include, but are not limited
to, statements about the initiation, timing, progress and results
of Mesoblast’s preclinical and clinical studies, and Mesoblast’s
research and development programs; Mesoblast’s ability to advance
product candidates into, enroll and successfully complete, clinical
studies, including multi-national clinical trials; Mesoblast’s
ability to advance its manufacturing capabilities; the timing or
likelihood of regulatory filings and approvals, manufacturing
activities and product marketing activities, if any; the
commercialization of Mesoblast’s product candidates, if approved;
regulatory or public perceptions and market acceptance surrounding
the use of stem-cell based therapies; the potential for Mesoblast’s
product candidates, if any are approved, to be withdrawn from the
market due to patient adverse events or deaths; the potential
benefits of strategic collaboration agreements and Mesoblast’s
ability to enter into and maintain established strategic
collaborations; Mesoblast’s ability to establish and maintain
intellectual property on its product candidates and Mesoblast’s
ability to successfully defend these in cases of alleged
infringement; the scope of protection Mesoblast is able to
establish and maintain for intellectual property rights covering
its product candidates and technology; estimates of Mesoblast’s
expenses, future revenues, capital requirements and its needs for
additional financing; Mesoblast’s financial performance;
developments relating to Mesoblast’s competitors and industry; and
the pricing and reimbursement of Mesoblast’s product candidates, if
approved. You should read this press release together with our risk
factors, in our most recently filed reports with the SEC or on our
website. Uncertainties and risks that may cause Mesoblast’s actual
results, performance or achievements to be materially different
from those which may be expressed or implied by such statements,
and accordingly, you should not place undue reliance on these
forward-looking statements. We do not undertake any obligations to
publicly update or revise any forward-looking statements, whether
as a result of new information, future developments or
otherwise.
Release authorized by the Chief Executive.
For more information, please contact:
Corporate Communications / Investors |
Media |
Paul Hughes |
Sumit Media |
T: +61 3 9639 6036 |
Grant Titmus |
E: investors@mesoblast.com |
T: +61 419 388 161 |
|
E: grant@sumitmedia.com.au |
|
|
|
Rubenstein |
|
Alex Davis-Isaac |
|
E:
adavisisaac@rubenstein.com |
|
|
Consolidated Income Statement
|
Three Months EndedSeptember
30, |
|
(in U.S. dollars, in
thousands, except per share amount) |
2021 |
|
|
2020 |
|
Revenue |
|
3,594 |
|
|
|
1,305 |
|
Research & development |
|
(9,328 |
) |
|
|
(19,278 |
) |
Manufacturing
commercialization |
|
(7,537 |
) |
|
|
(11,924 |
) |
Management and
administration |
|
(5,878 |
) |
|
|
(7,680 |
) |
Fair value remeasurement of
contingent consideration |
|
280 |
|
|
|
15,107 |
|
Other operating income and
expenses |
|
(178 |
) |
|
|
99 |
|
Finance costs |
|
(3,660 |
) |
|
|
(2,903 |
) |
Loss before income
tax |
|
(22,707 |
) |
|
|
(25,274 |
) |
Income tax (expense)/benefit |
|
62 |
|
|
|
730 |
|
Loss attributable to the
owners of Mesoblast Limited |
|
(22,645 |
) |
|
|
(24,544 |
) |
|
|
|
|
|
|
|
|
Losses per share from
continuing operations attributable to the ordinary
equity holders of the Group: |
Cents |
|
|
Cents |
|
Basic - losses per share |
|
(3.49 |
) |
|
|
(4.21 |
) |
Diluted - losses per share |
|
(3.49 |
) |
|
|
(4.21 |
) |
Consolidated Statement of Comprehensive Income
|
Three Months EndedSeptember
30, |
|
(in U.S. dollars, in
thousands) |
2021 |
|
|
2020 |
|
Loss for the period |
|
(22,645 |
) |
|
|
(24,544 |
) |
Other comprehensive
(loss)/income |
|
|
|
|
|
|
|
Items that may be reclassified to
profit and loss |
|
|
|
|
|
|
|
Exchange differences on
translation of foreign operations |
|
(349 |
) |
|
|
408 |
|
Items that will not be
reclassified to profit and loss |
|
|
|
|
|
|
|
Financial assets at fair value
through other comprehensive income |
|
154 |
|
|
|
81 |
|
Other comprehensive (loss)/income
for the period, net of tax |
|
(195 |
) |
|
|
489 |
|
Total comprehensive
losses attributable to the owners of Mesoblast
Limited |
|
(22,840 |
) |
|
|
(24,055 |
) |
Consolidated Balance Sheet
|
As ofSeptember30, |
|
|
As ofJune 30, |
|
(in U.S. dollars, in
thousands) |
2021 |
|
|
2021 |
|
Assets |
|
|
|
|
|
|
|
Current
Assets |
|
|
|
|
|
|
|
Cash & cash equivalents |
|
115,956 |
|
|
|
136,881 |
|
Trade & other
receivables |
|
5,627 |
|
|
|
4,842 |
|
Prepayments |
|
4,637 |
|
|
|
6,504 |
|
Total Current
Assets |
|
126,220 |
|
|
|
148,227 |
|
|
|
|
|
|
|
|
|
Non-Current
Assets |
|
|
|
|
|
|
|
Property, plant and
equipment |
|
2,750 |
|
|
|
3,021 |
|
Right-of-use assets |
|
8,485 |
|
|
|
9,119 |
|
Financial assets at fair value
through other comprehensive income |
|
2,234 |
|
|
|
2,080 |
|
Other non-current assets |
|
1,952 |
|
|
|
1,724 |
|
Intangible assets |
|
580,178 |
|
|
|
580,546 |
|
Total Non-Current
Assets |
|
595,599 |
|
|
|
596,490 |
|
Total
Assets |
|
721,819 |
|
|
|
744,717 |
|
|
|
|
|
|
|
|
|
Liabilities |
|
|
|
|
|
|
|
Current
Liabilities |
|
|
|
|
|
|
|
Trade and other payables |
|
16,263 |
|
|
|
19,598 |
|
Provisions |
|
19,649 |
|
|
|
18,710 |
|
Borrowings |
|
53,847 |
|
|
|
53,200 |
|
Lease liabilities |
|
3,140 |
|
|
|
2,765 |
|
Total Current
Liabilities |
|
92,899 |
|
|
|
94,273 |
|
|
|
|
|
|
|
|
|
Non-Current
Liabilities |
|
|
|
|
|
|
|
Deferred tax liability |
|
— |
|
|
|
— |
|
Provisions |
|
16,465 |
|
|
|
17,017 |
|
Borrowings |
|
42,651 |
|
|
|
41,045 |
|
Lease liabilities |
|
7,558 |
|
|
|
8,485 |
|
Deferred consideration |
|
2,500 |
|
|
|
2,500 |
|
Total Non-Current
Liabilities |
|
69,174 |
|
|
|
69,047 |
|
Total
Liabilities |
|
162,073 |
|
|
|
163,320 |
|
Net Assets |
|
559,746 |
|
|
|
581,397 |
|
|
|
|
|
|
|
|
|
Equity |
|
|
|
|
|
|
|
Issued Capital |
|
1,163,492 |
|
|
|
1,163,153 |
|
Reserves |
|
66,468 |
|
|
|
65,813 |
|
(Accumulated losses)/retained
earnings |
|
(670,214 |
) |
|
|
(647,569 |
) |
Total
Equity |
|
559,746 |
|
|
|
581,397 |
|
Consolidated Statement of Cash Flows
|
Three Months EndedSeptember
30, |
|
(in U.S. dollars, in
thousands) |
2021 |
|
|
2020 |
|
Cash flows from operating activities |
|
|
|
|
|
|
|
Commercialization revenue
received |
|
1,995 |
|
|
|
682 |
|
Government grants and tax
incentives received |
|
24 |
|
|
|
17 |
|
Payments to suppliers and
employees (inclusive of goods and services tax) |
|
(20,223 |
) |
|
|
(27,484 |
) |
Interest received |
|
4 |
|
|
|
13 |
|
Interest and other costs of
finance paid |
|
(1,407 |
) |
|
|
(1,389 |
) |
Income taxes paid |
|
— |
|
|
|
(6 |
) |
Net cash (outflows) in
operating activities |
|
(19,606 |
) |
|
|
(28,167 |
) |
|
|
|
|
|
|
|
|
Cash flows from
investing activities |
|
|
|
|
|
|
|
Investment in fixed
assets |
|
(99 |
) |
|
|
(81 |
) |
Net cash (outflows) in
investing activities |
|
(99 |
) |
|
|
(81 |
) |
|
|
|
|
|
|
|
|
Cash flows from
financing activities |
|
|
|
|
|
|
|
Payments of transaction costs
from borrowings |
|
(100 |
) |
|
|
— |
|
Proceeds from issue of
shares |
|
147 |
|
|
|
8,134 |
|
Payments for share issue
costs |
|
(104 |
) |
|
|
(897 |
) |
Payments for lease
liabilities |
|
(686 |
) |
|
|
(695 |
) |
Net cash inflows by
financing activities |
|
(743 |
) |
|
|
6,542 |
|
|
|
|
|
|
|
|
|
Net decrease in cash and cash
equivalents |
|
(20,448 |
) |
|
|
(21,706 |
) |
Cash and cash equivalents at
beginning of period |
|
136,881 |
|
|
|
129,328 |
|
FX gain/(losses) on the
translation of foreign bank accounts |
|
(477 |
) |
|
|
501 |
|
Cash and cash
equivalents at end of period |
|
115,956 |
|
|
|
108,123 |
|
Mesoblast (NASDAQ:MESO)
Historical Stock Chart
From Jul 2024 to Aug 2024
Mesoblast (NASDAQ:MESO)
Historical Stock Chart
From Aug 2023 to Aug 2024